Flow Cytometry Shared Resource

流式细胞术共享资源摘要 共济会癌症中心（MCC）流式细胞术共享资源（FCSR）的使命是提供 为MCC人员提供流式细胞术各方面的全面最先进的服务和培训， 成本效益的方式。该中心在共济会癌症研究大楼（MCRB）和 癌症和心血管研究大楼（CCRB）。几年前，FCSR是几个 明尼苏达大学学术健康中心（AHC）的独立流式细胞仪设施; 由一个单独的中心，部门或研究所管理。这些设施和AHC的董事 领导层决定将流式细胞仪设施合并到一个行政保护伞下， AHC的财政支持。这一新的大学流式细胞术资源（UFCR）提供了一个经济 AHC中心和研究所的规模，更多的资金购买设备，以及统一的支持 需要流式细胞仪设备和专业知识。它还允许MCC研究人员不居住在MCRB或 CCRB使用流式细胞仪设施而不是FCSR，并且仍然获得MCC的设备使用补贴。 FCSR是UFCR联合体4个成员中使用量最大的（约80%）。 计费小时）和仪器（10台流式细胞仪中的7台、3台细胞分选仪中的2台和2个数据分析工作中的2个 车站）。社发中心的日常业务主任是Paul Champoux先生;他由3名全职工作人员提供支助。 人事，AHC管理和5名成员组成的科学董事会。克里斯托弗·彭内尔博士 作为MCC流式细胞术的科学总监。他负责监督所有与癌症有关的 使用FCSR的项目，以及关于FCSR或其他3个UFCR成员的决定需要Dr. Pennell的协议;这确保FCSR和UFCR作为一个整体满足MCC的流式细胞术需求 研究人员FCSR定期与行业领导者合作，测试和采用新的流式细胞仪 技术，使其处于流式细胞术的前沿。因此，FCSR拥有了 在商业可用之前采用新技术进行改造。这些进步使 客户，并为教师提供工具，以保持与同行的竞争力，所有在非常低的费用。 未来5年的具体目标是：1）为MCC研究人员提供24/7的先进流 细胞计数仪器; 2）帮助MCC研究人员设计流式细胞术实验，数据采集， 3）教育MCC研究人员关于流式细胞术的原理和培训用户 4）对新试剂和设备进行beta测试，并不断升级设备;以及5） 与MCC研究人员分享流式细胞术的前沿进展。

Flow Cytometry Shared Resource Summary The mission of the Masonic Cancer Center (MCC) Flow Cytometry Shared Resource (FCSR) is to provide comprehensive state-of-the-art services and training in all aspects of flow cytometry to MCC personnel in a cost-effective manner. The FCSR has facilities in both the Masonic Cancer Research Building (MCRB) and the Cancer and Cardiovascular Research Building (CCRB). Several years ago, the FCSR was one of several independent flow cytometry facilities in the Academic Health Center (AHC) at the University of Minnesota; each was administered by a separate Center, Department, or Institute. The directors of these facilities and AHC leadership decided to merge the flow cytometry facilities under one administrative umbrella with centralized financial support from the AHC. This new University Flow Cytometry Resource (UFCR) provided an economy of scale, more funds to purchase equipment, and uniformity of support among the AHC centers and institutes that require flow cytometry equipment and expertise. It also allowed MCC researchers not housed in MCRB or CCRB to access flow cytometry facilities other than FCSR and still receive an MCC subsidy for equipment use. The FCSR is the largest of the 4 members in the UFCR consortium in terms of usage (approximately 80% of billed hours) and instrumentation (7 of 10 flow cytometers, 2 of 3 cell sorters, and 2 of 2 data analysis work stations). The FCSR Director of Daily Operations is Mr. Paul Champoux; he is supported by 3 full-time personnel, AHC administration, and a 5-member Board of Scientific Directors. Dr. Christopher Pennell serves on this Board as the Scientific Director of Flow Cytometry for MCC. He has oversight for all cancer-related projects that use FCSR, and decisions regarding FCSR or any of the other 3 UFCR members requires Dr. Pennell's agreement; this ensures that FCSR, and UFCR as a whole, meet the flow cytometry needs of MCC researchers. The FCSR regularly partners with industry leaders to test and adopt new flow cytometry technologies, keeping it at the cutting-edge of flow cytometry. As a result, the FCSR has had instrumentation retrofitted with new technologies prior to commercial availability. These advancements have benefitted customers and provided tools for the faculty to remain competitive with their peers, all at very low expense. The specific aims for the next 5 years are to 1) provide MCC researchers with 24/7 access to advanced flow cytometric instruments; 2) aid MCC researchers in the design of flow cytometry experiments, data acquisition, and data interpretation; 3) educate MCC researchers regarding the principles of flow cytometry and train users on self-service analyzers; 4) beta-test new reagents and equipment and continually upgrade equipment; and 5) share cutting-edge advancements in flow cytometry with MCC researchers.